Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - capsules - zidovudine 100 mg - zidovudine - zidovudine - retrovir oral formulations are indicated in anti-retroviral combination therapy for human immunodeficiency virus (hiv) infected adults and children.retrovir chemoprophylaxis is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - capsules - zidovudine 250 mg - zidovudine - zidovudine - retrovir oral formulations are indicated in anti-retroviral combination therapy for human immunodeficiency virus (hiv) infected adults and children.retrovir chemoprophylaxis is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants.

United States - English - NLM (National Library of Medicine)

viiv healthcare company - zidovudine (unii: 4b9xt59t7s) (zidovudine - unii:4b9xt59t7s) - zidovudine 100 mg - retrovir, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. retrovir is indicated for the prevention of maternal-fetal hiv-1 transmission [see dosage and administration (2.3)]. the indication is based on a dosing regimen that included 3 components: points to consider prior to initiating retrovir in pregnant women for the prevention of maternal-fetal hiv-1 transmission include: retrovir is contraindicated in patients who have had a potentially life-threatening hypersensitivity reaction (e.g., anaphylaxis, stevens-johnson syndrome) to any of the components of the formulations. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to retrovir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the o

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - bedaquiline fumarate 120.89mg equivalent to bedaquiline 100 mg;  ;   - tablet - 100 mg - active: bedaquiline fumarate 120.89mg equivalent to bedaquiline 100 mg     excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 20 - sirturo is indicated in adult (greater than or equal to 18 years) and pediatric patients (12 years to less than 18 years of age and weighing at least 30 kg) as part of combination therapy of pulmonary tuberculosis (tb) due to multi-drug resistant mycobacterium tuberculosis.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn. bhd. - bedaquiline fumarate -

Ireland - English - HPRA (Health Products Regulatory Authority)

viiv healthcare uk ltd - zidovudine - capsules hard - 100 milligram - nucleoside and nucleotide reverse transcriptase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

viiv healthcare uk ltd - zidovudine - oral solution - 100 mg/10ml - nucleoside and nucleotide reverse transcriptase inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 150 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin, quantity: 50 mg - tablet, chewable - excipient ingredients: quinoline yellow; saccharin sodium; magnesium stearate; purified talc; sunset yellow fcf; flavour; maize starch; sucrose - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

Ireland - English - HPRA (Health Products Regulatory Authority)

viiv healthcare uk ltd - zidovudine - concentrate for soln for inf - 10 mg/ml - nucleoside and nucleotide reverse transcriptase inhibitors